$MDGL News

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

B of A Securities Maintains Neutral on Madrigal Pharmaceuticals, Lowers Price Target to $542

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

The Bull Case For Madrigal Pharmaceuticals (MDGL) Could Change Following New Rezdiffra Cardiometabolic Data Release

Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound?

Madrigal (MDGL) Data Highlights Rezdiffra’s Cardiometabolic Benefits for MASH Patients at EASL Congress

Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026

Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Weakness

Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH

Madrigal Pharma Announces New Analyses Of Phase 3 Data And Real-World Evidence Demonstrating Rezdiffra Reduced Markers Of Cardiovascular And Liver-Related Risk In Patients With MASH

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk

Truist Securities Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $709

A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Strong Q1 2026 Earnings And Rezdiffra Sales Growth

Madrigal Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation

Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Lowers Price Target to $578

Evercore ISI Group Maintains Outperform on Madrigal Pharmaceuticals, Lowers Price Target to $649

Madrigal Pharmaceuticals Q1 Earnings Call Highlights

Madrigal Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary

Madrigal (MDGL) Q1 2026 Earnings Transcript